Boston, MA 10/07/2014 – According to reports, Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) reported that the last patient in the phase 2a ALS study had completed the last visit for the trial of trial of NurOwn. The test was conducted at the Hadassah Medical Center in Jerusalem.
Insights of the test:
All the preliminary tests have been conducted successfully by Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI). As per the information, final results of the entire study will be disclosed after the statistical analysis in 4Q2014. BCLI has been involved in this study for a long time. Previously it reported preliminary data from this study at Joint Congress of European Neurology. Data was represented by Professor Dimitrios Karussis of Hadassah; the principal investigator of this study. Professor Karussis told reporters that he was very pleased to announce the successful conclusion of the second study of NurOwn.
Management of the company is delighted after the completion of initial phase of this study and looking forward to its results. According to Dr. Yael Gothelf, PhD, Vice President of Regulatory and Scientific Affairs at Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI), progress of this study is very fast. The completion of last patient visit is very important for the entire study. So far the efficacy and safety profile that BCLI has come across is very satisfying and up to the mark. Now the entire focus of the company will be on finishing analysis as soon as possible and then reveal the final results of the tests.
While talking to reporters, Professor Karussis said that he had treated around 30 ALS patients with NurOwn in a few compassionate use treatments and a couple of clinical trials. The emergency profile and efficacy factor was appreciable. The main objective of this single-center dose-ranging study is to find out tools for ensuring complete safety of a single administration of NurOwn. It can be done through intramuscular and intrathecal injections.
